{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:57:26Z","timestamp":1777111046717,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Study objectives:<\/jats:bold> While zolpidem is considered as an example of a gender effect on drug response, there is insufficient evidence to reach a consensus. This study aimed to investigate gender differences in adverse events (AEs) of zolpidem.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We estimated the difference between the reporting odds ratios (RORs) calculated in gender subgroups for the AEs signals detected in data mining using 2015\u20132019 Korea voluntary adverse drug events reporting system (KAERS) data. Different reporting risk by gender was evaluated by using the log RORs being significantly different by gender at the 5% significance level and the 95% confidence intervals of the gender ROR.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 94 AE signals were detected. Among these, 35 signals showed significant disparities by gender at the 5% level or were detected only in one gender. When categorized by similarity of AEs, parasomnia including somnambulism and paroniria, and cardiovascular disorders including coronary thrombosis had higher reporting risks in women. Men were more likely to report cognitive disorders such as delirium, insomnia related disorders, and movement disorders. Among all AEs with gender differences in reporting risk, the difference in somnambulism was the most consistent and substantial.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> For several AEs associated with zolpidem, gender-based reporting disparities were evident. Notably, women exhibited a higher susbeptibility to somnambulism, potentially serious adverse effects of zolpidem. This underscores the need for further investigation into the underlying factors influencing these gender-specific reporting patterns.<\/jats:p>","DOI":"10.3389\/fphar.2023.1256245","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T21:30:25Z","timestamp":1699738225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015\u20132019"],"prefix":"10.3389","volume":"14","author":[{"given":"Kyung-In","family":"Joung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2869.2011.00919.x","article-title":"Spontaneous adverse event reports associated with zolpidem in Australia 2001\u20132008","volume":"20","author":"Ben\u2010Hamou","year":"2011","journal-title":"J. sleep Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.sleep.2010.07.011","article-title":"Prevalence of different parasomnias in the general population","volume":"11","author":"Bjorvatn","year":"2010","journal-title":"Sleep. Med."},{"key":"B3","unstructured":"Zolpidem tartrate (Stilnox Tab.) label information2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1314","DOI":"10.4088\/JCP.13m08901","article-title":"Clinical correlates of zolpidem-associated complex sleep-related behaviors: age effect","volume":"75","author":"Chen","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.2147\/NDT.S48152","article-title":"A comparison of complex sleep behaviors with two short-acting Z-hypnosedative drugs in nonpsychotic patients","volume":"9","author":"Chen","year":"2013","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"B6","volume-title":"Risk of next-day impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edular, and Zolpimist)","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5455\/bcp.20130527020102","article-title":"Sleep related amnestic behaviors due to zolpidem","volume":"24","author":"Cuba\u0142a","year":"2014","journal-title":"Klinik Psikofarmakoloji B\u00fclteni-Bulletin Clin. Psychopharmacol."},{"key":"B8","unstructured":"Zolpidem tartrate tablet label information2023"},{"key":"B9","first-page":"535","article-title":"\u201cI did what?\u201d Zolpidem and the courts","volume":"39","author":"Daley","year":"2011","journal-title":"J. Am. Acad. Psychiatry Law Online"},{"key":"B10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/s0924-977x(02)00153-0","article-title":"Effects of zolpidem 10 mg, zopiclone 7.5 mg and flunitrazepam 1 mg on night-time motor activity","volume":"13","author":"Denise","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in The Netherlands: an explorative observational study","volume":"85","author":"de Vries","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2165\/0023210-200822120-00005","article-title":"Hypnosedative-induced complex behaviours: incidence, mechanisms and management","volume":"22","author":"Dolder","year":"2008","journal-title":"CNS drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.pharmthera.2005.04.014","article-title":"Treating insomnia: current and investigational pharmacological approaches","volume":"112","author":"Ebert","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"24927","DOI":"10.52965\/001c.24927","article-title":"Zolpidem: efficacy and side effects for insomnia","volume":"9","author":"Edinoff","year":"2021","journal-title":"Health Psychol. Res."},{"key":"B15","unstructured":"Zolpidem tartrate 10 mg tablets2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B17","unstructured":"FDA drug safety communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR2023"},{"key":"B18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/JCP.0000000000001026","article-title":"Zolpidem and gender: are women really at risk?","volume":"39","author":"Greenblatt","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"B19","first-page":"435","article-title":"Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences","volume":"293","author":"Greenblatt","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.34161\/johta.2018.6.1.006","article-title":"Signal detection of adverse drug reaction of zolpidem using the Korea adverse event reporting system database","volume":"6","author":"Han","year":"2018","journal-title":"J. Health Tech. Assess."},{"key":"B21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/pds.5004","article-title":"Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death","volume":"29","author":"Harbourt","year":"2020","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/pds.4155","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden","volume":"26","author":"Holm","year":"2017","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S2215-0366(16)30209-7","article-title":"Gender-neutral mental health research is sex and gender biased","volume":"4","author":"Howard","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/jpm12101645","article-title":"Hypnotics use is associated with elevated incident atrial fibrillation: a propensity-score matched analysis of cohort study","volume":"12","author":"Hu","year":"2022","journal-title":"J. Personalized Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.4088\/JCP.12m08181","article-title":"Relationship between zolpidem use and stroke risk: a Taiwanese population-based case-control study","volume":"74","author":"Huang","year":"2013","journal-title":"J. Clin. psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.chest.2017.01.026","article-title":"Insomnia and risk of cardiovascular disease","volume":"152","author":"Javaheri","year":"2017","journal-title":"Chest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17545","DOI":"10.1038\/s41598-020-74000-4","article-title":"Gender differences in adverse event reports associated with antidiabetic drugs","volume":"10","author":"Joung","year":"","journal-title":"Sci. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2217\/pgs-2020-0047","article-title":"Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events","volume":"21","author":"Joung","year":"","journal-title":"Pharmacogenomics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3904\/kjim.2016.282","article-title":"Use of hypnotics and the risk of or mortality from heart disease: a meta-analysis of observational studies","volume":"33","author":"Kim","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"01583","DOI":"10.4088\/PCC.13m01583","article-title":"Association of hypnotics with stroke risk: a population-based case-control study","volume":"16","author":"Lee","year":"2014","journal-title":"Prim. Care Companion CNS Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/1119-0388.198134","article-title":"Gender differences in the occurrences and pattern of adverse drug reactions in psychiatric patients: a prospective observational study","volume":"20","author":"Lucca","year":"2017","journal-title":"Trop. J. Med. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.diabet.2009.02.001","article-title":"How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey","volume":"35","author":"Mosnier-Pudar","year":"2009","journal-title":"Diabetes and metabolism"},{"key":"B33","first-page":"963","article-title":"Temporal pattern discovery for trends and transient effects: its application to patient records","author":"Nor\u00e9n","year":"2008"},{"key":"B34","volume-title":"Hypnotic hazards: adverse effects of zolpidem and other z-drugs","author":"Olson","year":"2008"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.4103\/0976-500X.120955","article-title":"Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two \u201cchallenging\u201d case reports","volume":"4","author":"Palleria","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"01363","DOI":"10.4088\/PCC.12br01363","article-title":"Two cases of zolpidem-associated homicide","volume":"14","author":"Paradis","year":"2012","journal-title":"Prim. Care Companion CNS Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5664\/jcsm.5574","article-title":"Gender differences in the efficacy and safety of chronic nightly zolpidem","volume":"12","author":"Roehrs","year":"2016","journal-title":"J. Clin. Sleep Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.1796","article-title":"Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers","volume":"18","author":"Shin","year":"2009","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/2047487312460020","article-title":"Insomnia and risk of cardiovascular disease: a meta-analysis","volume":"21","author":"Sofi","year":"2014","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.smrv.2017.01.005","article-title":"Medication induced sleepwalking: a systematic review","volume":"37","author":"Stallman","year":"2018","journal-title":"Sleep. Med. Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.euroneuro.2003.09.007","article-title":"Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study","volume":"14","author":"Voshaar","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1089\/jwh.2009.1784","article-title":"Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression","volume":"19","author":"Weinberger","year":"2010","journal-title":"J. women's health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/NMD.0000000000001074","article-title":"Zolpidem-associated consequences: an updated literature review with case reports","volume":"208","author":"Westermeyer","year":"2020","journal-title":"J. Nerv. Ment. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5664\/jcsm.6452","article-title":"Spontaneous adverse event reports associated with zolpidem in the United States 2003\u20132012","volume":"13","author":"Wong","year":"2017","journal-title":"J. Clin. sleep Med."},{"key":"B47","article-title":"Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action","volume-title":"Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action","year":"2002"},{"key":"B48","doi-asserted-by":"publisher","first-page":"19150","DOI":"10.1038\/s41598-021-98689-z","article-title":"Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem","volume":"11","author":"Yoon","year":"2021","journal-title":"Sci. Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic analysis of adverse event reports for sex differences in adverse drug events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci. Rep."},{"key":"B50","first-page":"23777","article-title":"Non-benzodiazepine hypnotic drug is correlated with decreased risk of ischemic stroke","volume":"9","author":"Zhu","year":"2016","journal-title":"Int. J. Clin. Exp. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1256245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T21:30:30Z","timestamp":1699738230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1256245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":50,"alternative-id":["10.3389\/fphar.2023.1256245"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1256245","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"article-number":"1256245"}}